Oral disease-modifying treatments for multiple sclerosis: The story so far

CNS Drugs

Volumn 21, Issue 6, 2007, Pages 483-502

  Kieseier, Bernd C ^a   Wiendl, Heinz ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ATORVASTATIN; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; CYCLOSPORIN; ESTRIOL; FINGOLIMOD; FUMARIC ACID; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; IBUDILAST; IMMUNOGLOBULIN; INTERFERON BETA SERINE; LAQUINIMOD; METHOTREXATE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PREDNISONE; RAPAMYCIN; ROLIPRAM; ROQUINIMEX; SB 683699; SIMVASTATIN; TEMSIROLIMUS; TERIFLUNOMIDE; THIOCTIC ACID; UNINDEXED DRUG; URIC ACID DERIVATIVE;

ALLERGIC ENCEPHALOMYELITIS; ANTIGEN PRESENTING CELL; B LYMPHOCYTE ACTIVATION; BLOOD BRAIN BARRIER; BREAST CANCER; CELL INTERACTION; CLINICAL TRIAL; COMMON COLD; DEMYELINATION; DIABETES MELLITUS; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DYSLIPIDEMIA; FLUSHING; GASTROINTESTINAL DISEASE; GENETIC SUSCEPTIBILITY; HEART INFARCTION; HELPER CELL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNE DYSREGULATION; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; INJECTION SITE REACTION; KIDNEY CANCER; LIVER NECROSIS; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOCYTOPENIA; MENSTRUATION DISORDER; MONOTHERAPY; MOUTH INFLAMMATION; MOUTH ULCER; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; NAUSEA; NEUROPSYCHOLOGICAL TEST; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCYTOPENIA; PERIPHERAL EDEMA; PRIORITY JOURNAL; RASH; RESPIRATORY TRACT INFECTION; RETINA MACULA EDEMA; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; T LYMPHOCYTE ACTIVATION; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, ORAL; ANIMALS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; META-ANALYSIS; MODELS, IMMUNOLOGICAL; MULTIPLE SCLEROSIS; TREATMENT OUTCOME;

EID: 34249818493     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200721060-00005     Document Type: Review

References (142)

1. Hohlfeld R, Wiendl H. The ups and downs of multiple sclerosis therapeutics. Ann Neurol 2001; 49: 281-4
2. Kieseier BC, Hartung HP. Current disease-modifying therapies in multiple sclerosis. Semin Neurol 2003; 23: 133-46
3. Wiendl H, Kieseier BC. Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies. Expert Opin Investig Drugs 2003; 12: 689-712
4. Hohlfeld R, Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci U S A 2004; 101: 14599-606
5. Fox RJ, Ransohoff RM. New directions in MS therapeutics: vehicles of hope. Trends Immunol 2004; 25: 632-6
6. Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 2002; 16: 183-200
7. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-97
8. Frohman EM, Racke MK, Raine CS. Multiple sclerosis: the plaque and its pathogenesis. N Engl J Med 2006; 354: 942-55
9. Hafler DA, Slavik JM, Anderson DE, et al. Multiple sclerosis. Immunol Rev 2005; 204: 208-31
10. Hemmer B, Archelos JJ, Hartung HP. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 2002; 3: 291-301
11. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000; 343: 938-52
12. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23: 683-747
13. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis: principles, problems and perspectives. Brain 1997; 120: 865-916
14. Steinman L. Multiple sclerosis: a two-stage disease. Nat Immunol 2001; 2: 762-4
15. Lassmann H, Bruck W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001; 7: 115-21
16. Archelos JJ, Storch MK, Hartung HP. The role of B cells and autoantibodies in multiple sclerosis. Ann Neurol 2000; 47: 694-706
17. Bjartmar C, Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol 2001; 14: 271-8
18. Zipp F, Krammer PH, Weller M. Immune (dys)regulation in multiple sclerosis: role of the CD95-CD95 ligand system. Immunol Today 1999; 20: 550-4
19. Yong VW. Differential mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology 2002; 59: 802-8
20. Polman C, Barkhof F, Kappos L, et al. Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study. Mult Scler 2003; 9: 342-8
21. Farina C, Weber MS, Meinl E, et al. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol 2005; 4: 567-75
22. Filippi M, Wolinsky JS, Comi G. Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Neurol 2006; 5: 213-20
23. Teva Pharmaceutical Industries Ltd. Copaxone® (glatiramer acetate for injection) [online]. Available from URL: http:// www.tevapharm.com/research/ products_ms.asp#Copaxone Injection [Accessed 2007 May 1]
24. Palace J, Rothwell P. New treatments and azathioprine in multiple sclerosis. Lancet 1997; 350: 261
25. Yudkin PL, Ellison GW, Ghezzi A, et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991; 338: 1051-5
26. Massacesi L, Parigi A, Barilaro A, et al. Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging. Arch Neurol 2005; 62: 1843-7
27. Fernandez O, Guerrero M, Mayorga C, et al. Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis: a two-year pilot study. J Neurol 2002; 249: 1058-62
28. Lus G, Romano F, Scuotto A, et al. Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment. Eur Neurol 2004; 51: 15-20
29. Markovic-Plese S, Bielekova B, Kadom N, et al. Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon beta-1b. Neurology 2003; 60: 1849-51
30. Havrdova E, Zivadinov R, Krasensky J, et al. Efficacy results from a randomised, double-blind, placebo-controlled study of intramuscular interferon beta-1a, azathioprine, and corticosteroid combination therapy in patients with relapsing-remitting multiple sclerosis. Mult Scler 2006; 12 Suppl. 1: S11
31. Gray O, McDonnell GV, Forbes RB. Methotrexate for multiple sclerosis. Cochrane Database Syst Rev 2004; (2): CD003208
32. Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995; 37: 30-40
33. Calabresi PA, Wilterdink JL, Rogg JM, et al. An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS. Neurology 2002; 58: 314-7
34. Serkova NJ, Christians U, Benet LZ. Biochemical mechanisms of cyclosporine neurotoxicity. Mol Interv 2004; 4: 97-107
35. Webster AC, Woodroffe RC, Taylor RS, et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005; 331: 810-21
36. Kappos L, Patzold U, Dommasch D, et al. Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis: results of the German multicenter study. Ann Neurol 1988; 23: 56-63
37. The Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporin in chronic progressive multiple sclerosis: a randomised, double-blinded, placebo-controlled clinical trial. Ann Neurol 1990; 27: 591-605
38. Zhao GJ, Li DK, Wolinsky JS, et al. Clinical and magnetic resonance imaging changes correlate in a clinical trial monitoring cyclosporine therapy for multiple sclerosis: the MS study group. J Neuroimaging 1997; 7: 1-7
39. Goodin DS, Frohman EM, Garmany Jr GP, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58: 169-78
40. Schneider-Gold C, Hartung HP, Gold R. Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroimmunological diseases. Muscle Nerve 2006; 34: 284-91
41. Frohman EM, Brannon K, Racke MK, et al. Mycophenolate mofetil in multiple sclerosis. Clin Neuropharmacol 2004; 27: 80-3
42. Vermersch P, Stojkovic T, de Seze J. Mycophenolate mofetil and neurological diseases. Lupus 2005; 14 Suppl. 1: S42-5
43. Ahrens N, Salama A, Haas J. Mycophenolate-mofetil in the treatment of refractory multiple sclerosis. J Neurol 2001; 248: 713-4
44. Vermersch P, Waucquier N, Michelin E, et al. Combination of IFNbeta-1a (Avonex) and mycophenolate mofetil (Cellcept) in multiple sclerosis. Eur J Neurol 2007; 14: 85-9
45. Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 1992; 340: 952-6
46. Sipe JC. Cladribine for multiple sclerosis: review and current status. Expert Rev Neurother 2005; 5: 721-7
47. Beutler E, Sipe JC, Romine JS, et al. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci U S A 1996; 93: 1716-20
48. Sipe JC, Romine JS, Koziol JA, et al. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994; 344: 9-13
49. Romine JS, Sipe JC, Koziol JA, et al. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians 1999; 111: 35-44
50. Sipe JC, Romine JS, Koziol JA, et al. Development of cladribine treatment in multiple sclerosis. Mult Scler 1996; 1: 343-7
51. Filippi M, Rovaris M, Iannucci G, et al. Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology 2000; 55: 1714-8
52. Filippi M, Rovaris M, Rice GP, et al. The effect of cladribine on T(1) 'black hole' changes in progressive MS. J Neurol Sci 2000; 176: 42-4
53. Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 2000; 54: 1145-55
54. Brousil JA, Roberts RJ, Schlein AL. Cladribine: an investigational immunomodulatory agent for multiple sclerosis. Ann Pharmacother 2006; 40: 1814-21
55. National Multiple Sclerosis Society. Clinical trials in multiple sclerosis 2006: planned, in progress, recently completed [online]. Available from URL: http://www.nationalmssociety.org/docs/HOM/clinicaltrials.pdf [Accessed 2007 Apr 12]
56. Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003; 35 Suppl. 3: 7-14S
57. Farrell R, Heaney D, Giovannoni G. Emerging therapies in multiple sclerosis. Expert Opin Emerg Drugs 2005; 10: 797-816
58. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006; 5 (8): 671-88
59. Mancuso A, Sternberg CN. New treatment approaches in metastatic renal cell carcinoma. Curr Opin Urol 2006; 16: 337-41
60. Kappos L, Barkhof F, Desmet A. The effect of oral temsirolimus on new magnetic resonance imaging scan lesions, brain atrophy, and the number of relapses in multiple sclerosis: results from a randomised, controlled clinical trial. J Neurol 2005; 252 Suppl. 2: S46
61. Hashkes PJ, Laxer RM. Update on the medical treatment of juvenile idiopathic arthritis. Curr Rheumatol Rep 2006; 8: 450-8
62. Korn T, Magnus T, Toyka K, et al. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide: mechanisms independent of pyrimidine depletion. J Leukoc Biol 2004; 76: 950-60
63. Kaplan MJ. Leflunomide Aventis Pharma. Curr Opin Investig Drugs 2001; 2: 222-30
64. Korn T, Toyka K, Hartung HP, et al. Suppression of experimental autoimmune neuritis by leflunomide. Brain 2001; 124: 1791-802
65. Smolen JS, Emery P, Kalden JR, et al. The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy. J Rheumatol 2004; 71 Suppl.: 13-20
66. O'Connor PW, Li D, Freedman MS, et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006; 66: 894-900
67. Brunmark C, Runstrom A, Ohlsson L, et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol 2002; 130: 163-72
68. Jonsson S, Andersson G, Fex T, et al. Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quino-linecarboxamides for treatment of autoimmune disorders: structure-activity relationship. J Med Chem 2004; 47: 2075-88
69. Runstrom A, Leanderson T, Ohlsson L, et al. Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice. J Neuroimmunol 2006; 173: 69-78
70. Yang JS, Xu LY, Xiao BG, et al. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol 2004; 156: 3-9
71. Andersen O, Lycke J, Tollesson PO, et al. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology 1996; 47: 895-900
72. Karussis DM, Meiner Z, Lehmann D, et al. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology 1996; 47: 341-6
73. Jönsson S, Andersson G, Fex T, et al. Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quino-linecarboxamides for treatment of autoimmune disorders: structure-activity relationship. J Med Chem 2004; 47: 2075-88
74. Polman C, Barkhof F, Sandberg-Wollheim M, et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005; 64: 987-91
75. Dyke HJ, Montana JG. Update on the therapeutic potential of PDE4 inhibitors. Expert Opin Investig Drugs 2002; 11: 1-13
76. Bielekova B, Lincoln A, McFarland H, et al. Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases. J Immunol 2000; 164: 1117-24
77. Fujimoto T, Sakoda S, Fujimura H, et al. Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats. J Neuroimmunol 1999; 95: 35-42
78. Jung S, Huitinga I, Schmidt B, et al. Selective elimination of macrophages by dichlormethylene diphosphonate-containing liposomes suppresses experimental autoimmune neuritis. J Neurol Sci 1993; 119: 195-202
79. Sommer N, Loschmann PA, Northoff GH, et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat Med 1995; 1: 244-8
80. Feng J, Misu T, Fujihara K, et al. Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1/Th2 balance and NKT cell subset in multiple sclerosis. Mult Scler 2004; 10: 494-8
81. Friese MA, Montalban X, Willcox N, et al. The value of animal models for drug development in multiple sclerosis. Brain 2006; 129 (Pt 8): 1940-52
82. Pershadsingh HA. Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis? Expert Opin Investig Drugs 2004; 13: 215-28
83. Dello Russo C, Gavrilyuk V, Weinberg G, et al. Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J Biol Chem 2003; 278: 5828-36
84. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-89
85. Storer PD, Xu J, Chavis J, et al. Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. J Neuroimmunol 2005; 161: 113-22
86. Diab A, Deng C, Smith JD, et al. Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J Immunol 2002; 168: 2508-15
87. Feinstein DL, Galea E, Gavrilyuk V, et al. Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol 2002; 51: 694-702
88. Klotz L, Schmidt M, Giese T, et al. Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. J Immunol 2005; 175: 4948-55
89. Pershadsingh HA, Heneka MT, Saini R, et al. Effect of pioglitazone treatment in a patient with secondary multiple sclerosis. J Neuroinflammation. Epub 2004 Apr 20
90. ClinicalTrials.gov, a service of the US National Institutes of Health. Pilot test of ACTOS in multiple sclerosis: safety and tolerability [online]. Available from URL: http://clinical trials.gov/ct/show/NCT00242177?order=1 [Accessed 2007 May 1]
91. Brinkmann V. FTY720: mechanism of action and potential benefit in organ transplantation. Yonsei Med J 2004; 45: 991-7
92. Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002; 277: 21453-7
93. Chiba K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol Ther 2005; 108: 308-19
94. Cyster JG. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 2005; 23: 127-59
95. Yopp AC, Fu S, Honig SM, et al. FTY720-enhanced T cell homing is dependent on CCR2, CCR5, CCR7, and CXCR4: evidence for distinct chemokine compartments. J Immunol 2004; 173: 855-65
96. Muller H, Hofer S, Kaneider N, et al. The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. Eur J Immunol 2005; 35: 533-45
97. Budde K, Schmouder RL, Brunkhorst R, et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 2002; 13: 1073-83
98. Fujino M, Funeshima N, Kitazawa Y, et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 2003; 305: 70-7
99. Rausch M, Hiestand P, Foster CA, et al. Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. J Magn Reson Imaging 2004; 20: 16-24
100. Webb M, Tham CS, Lin FF, et al. Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J Neuroimmunol 2004; 153: 108-21
101. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355: 1124-40
102. O'Connor PW, Antel J, Comi G. Oral FTY720 in relapsing MS: results of the dose-blinded, active drug extension phase of a phase II study [abstract]. Neurology 2006; 66: A123
103. Budde K, Schutz M, Glander P, et al. FTY720 (fingolimod) in renal transplantation. Clin Transplant 2006; 20 Suppl. 17: 17-24
104. Massberg S, von Andrian UH. Fingolimod and sphingosine-1-phosphate: modifiers of lymphocyte migration. N Engl J Med 2006; 355: 1088-91
105. Schimrigk S, Brune N, Hellwig K, et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol 2006; 13 (6): 604-10
106. Kappos L, Miller D, MacManus DG, et al. BG00012, a novel oral fumarate, is effective in patients with relapsing-remitting multiple sclerosis. Mult Scler 2006; 12: S85
107. Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399-402
108. Menge T, Hartung HP, Stuve O. Statins: a cure-all for the brain? Nat Rev Neurosci 2005; 6: 325-31
109. Aktas O, Waiczies S, Smorodchenko A, et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med 2003; 197: 725-33
110. Paintlia AS, Paintlia MK, Khan M, et al. HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis. Faseb J 2005; 19: 1407-21
111. Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420: 78-84
112. Rizvi SA, Bashir K. Other therapy options and future strategies for treating patients with multiple sclerosis. Neurology 2004; 63: S47-54
113. Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004; 363: 1607-8
114. Stuve O, Youssef S, Weber MS, et al. Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest 2006; 116: 1037-44
115. Sicotte NL, Liva SM, Klutch R, et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol 2002; 52: 421-8
116. Hooper DC, Spitsin S, Kean RB, et al. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A 1998; 95 (2): 675-80
117. Scott GS, Spitsin SV, Kean RB, et al. Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc Natl Acad Sci U S A 2002; 99: 16303-8
118. ClinicalTrials.gov, a service of the US National Institutes of Health. Treatment of multiple sclerosis using over the counter inosine [online]. Available from URL: http://clinicaltrials.gov/ ct/show/NCT00067327?order=1 [Accessed 2007 May 1]
119. Archelos JJ, Previtali SC, Hartung HP. The role of integrins in immune-mediated diseases of the nervous system. Trends Neurosci 1999; 22: 30-8
120. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006; 354: 610-21
121. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-23
122. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354 (9): 899-910
123. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353: 369-74
124. Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353: 375-81
125. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005; 353: 362-8
126. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006; 354: 924-33
127. US Food and Drug Administration. Patient checklist [online]. Available from URL: http://www.fda.gov [Accessed 2007 Mar 8]
128. US Food and Drug Administration. Natalizumab information. Risk minimization plan: summary of TOUCH [online]. Available from URL: http://www.fda.gov/cder/drug/infopage/ natalizumab/riskMAP.pdf [Accessed 2007 Mar 8]
129. Department of Health and Human Services, Public Health Service, Food and Drug Administration. Letter to Dr Cohen [online]. Available from URL: http://www.fda.gov/cder/foi/ appletter/2006/125104s015LTR.pdf [Accessed 2007 Mar 8]
130. More fallout: Glaxo halts MS drug trial on Tysabri recall [online]. Available from URL: http://www.thisisms.com/article196.html [Accessed 2007 May 1]
131. Elices MJ. BX-471 Berlex. Curr Opin Investig Drugs 2002; 3: 865-9
132. Zipp F, Hartung HP, Hillert J, et al. Blockade of chemokine signaling in patients with multiple sclerosis. Neurology 2006; 67 (10): 1880-3
133. Hartung HP, Kieseier BC. The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J Neuroimmunol 2000; 107: 140-7
134. Yong VW. Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci 2005; 6: 931-44
135. Brundula V, Rewcastle NB, Metz LM, et al. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 2002; 125: 1297-308
136. Popovic N, Schubart A, Goetz BD, et al. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol 2002; 51: 215-23
137. Kieseier BC, Seifert T, Giovannoni G, et al. Matrix metalloproteinases in inflammatory demyelination: targets for treatment. Neurology 1999; 53: 20-5
138. Yong VW, Wells J, Giuliani F, et al. The promise of minocycline in neurology. Lancet Neurol 2004; 3: 744-51
139. Metz LM, Zhang Y, Yeung M, et al. Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis [letter]. Ann Neurol 2004; 55: 756
140. Marracci GH, McKeon GP, Marquardt WE, et al. Alpha lipoic acid inhibits human T-cell migration: implications for multiple sclerosis. J Neurosci Res 2004; 78: 362-70
141. Morini M, Roccatagliata L, Dell'Eva R, et al. Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. J Neuroimmunol 2004; 148: 146-53
142. Yadav V, Marracci G, Lovera J, et al. Lipoic acid in multiple sclerosis: a pilot study. Mult Scler 2005; 11: 159-65